CCDC6-RET [V804M]/BaF3
CBP73216
詢(xún) 價(jià)
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. Introduction | |
| Cell Line Name： | CCDC6-RET [V804M]/BaF3 |
| Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Application: | Anti-proliferation assay and PD assay |
| Freeze Medium: | 90% FBS+10% DMSO |
| Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
| Mycoplasma Status: | Negative |
| II. Background | |
|
CCDC6, coiled-coil domain containing 6, has been shown to play a role in the DNA damaging signaling pathway acting as a substrate of ATM (PMID: 17420723). CCDC6 fusions with RET (PMID: 23154560, PMID: 26078337) and BRAF (PMID: 26314551) have been observed in multiple cancer types. |
|
| III. Representative Data | |
|
1. CCDC6-RET V804M/BaF3
|
|
|
2. Sanger of CCDC6-RET [V804M]/BaF3
Figure 2. Breakpoint of CCDC6-RET V804M/BaF3
Figure 3. Point mutation of CCDC6-RET V804M/BaF3 |
|
|
3.Anti-proliferation assay
Figure 4. CTG Assay for CCDC6-Ret V804M BaF3 Proliferation. |
|
